Influenza vaccine manufacturing: Effect of inactivation, splitting and site of manufacturing. Comparison of influenza vaccine production processes

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Kon, Theone C ^a   Onu, Adrian ^b   Berbecila, Laurentiu ^b   Lupulescu, Emilia ^b   Ghiorgisor, Alina ^b   Kersten, Gideon F ^a   Cui, Yi Qing ^a   Amorij, Jean Pierre ^a   Van Der Pol, Leo ^a  

^a Institute for Translational Vaccinology   (Netherlands)

^b Ion Cantacuzino National Institute of Microbiology   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ETHER; FORMALDEHYDE; HEMAGGLUTININ; INFLUENZA VACCINE; POLYSORBATE; PROPIOLACTONE; TRITON X 100; INACTIVATED VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ARTICLE; CENTRIFUGATION; DRUG PURIFICATION; DRUG RELEASE; DRUG STABILITY; EVAPORATION; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; INFLUENZA A VIRUS (H3N2); INTERMETHOD COMPARISON; NONHUMAN; ULTRACENTRIFUGATION; VACCINE PRODUCTION; VIRUS INACTIVATION; BIOSYNTHESIS; COMPARATIVE STUDY; FILTRATION; MASS SPECTROMETRY; METABOLISM; PHOTON CORRELATION SPECTROSCOPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; ULTRASTRUCTURE; VIRION;

DYNAMIC LIGHT SCATTERING; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FILTRATION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA VACCINES; MASS SPECTROMETRY; VACCINES, INACTIVATED; VIRION;

EID: 84961231047     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150700     Document Type: Article

References (38)

1. Hendriks J, Holleman M, de Boer O, de Jong P, LuytjesW(2011) An international technology platform for influenza vaccines. Vaccine 29 Suppl 1: A8-11. doi: 10.1016/j.vaccine.2011.04.124 PMID: 21684431
2. Amorij JP, HinrichsW, Frijlink HW, Wilschut JC, Huckriede A (2010) Needle-free influenza vaccination. Lancet Infect Dis 10: 699-711. doi: 10.1016/S1473-3099(10)70157-2 PMID: 20883966
3. Stohr K (2014) Perspective: Ill prepared for a pandemic. Nature 507: S20-21. PMID: 24611175
4. Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WL (2008) Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res 25: 1256-1273. doi: 10.1007/ s11095-008-9559-6 PMID: 18338241
5. Soema PC, Rosendahl Huber SK, Willems GJ, Jiskoot W, Kersten GF, Amorij JP (2015) Influenza Tcell epitope-loaded virosomes adjuvanted with CpG as a potential influenza vaccine. Pharm Res 32: 1505-1515. doi: 10.1007/s11095-014-1556-3 PMID: 25344321
6. McElhaney JE, Meneilly GS, Lechelt KE, Bleackley RC (1994) Split-virus influenza vaccines: do they provide adequate immunity in the elderly? J Gerontol 49: M37-43. PMID: 8126350
7. Wu J, Liu SZ, Dong SS, Dong XP, Zhang WL, Lu M, et al. (2010) Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial. Vaccine 28: 6221-6227. doi: 10.1016/j.vaccine.2010.07.008 PMID: 20638454
8. Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, et al. (2008) Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 4: e1000138. doi: 10.1371/journal.ppat.1000138 PMID: 18769719
9. Crovari P, Alberti M, Alicino C (2011) History and evolution of influenza vaccines. J Prev Med Hyg 52: 91-94.
10. Beyer WE, Palache AM, Osterhaus AD (1998) Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split Vaccines: A Review and Meta-Analysis of the Literature. Clin Drug Investig 15: 1-12. PMID: 18370460
11. Ennis FA, Mayner RE, Barry DW, Manischewitz JE, Dunlap RC, Verbonitz MW, et al. (1977) Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines. J Infect Dis 136 Suppl: S397-406. PMID: 606763
12. Davenport FM, Hennessy AV, Brandon FM, Webster RG, Barrett CD Jr., Lease GO (1964) Comparisons of Serologic and Febrile Responses in Humans to Vaccination with Influenza a Viruses or Their Hemagglutinins. J Lab Clin Med 63: 5-13. PMID: 14102904
13. Brandon FB, Cox F, Lease GO, Timm EA, Quinn E, McLean IW Jr. (1967) Respiratory virus vaccines. 3. Some biological properties of Sephadex-purified ether-extracted influenza virus antigens. J Immunol 98: 800-805. PMID: 5336967
14. Lina B, Fletcher MA, Valette M, Saliou P, Aymard M (2000) A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly. Biologicals 28: 95-103. PMID: 10885616
15. Sciencelab (2013) Material Safety Data Sheet Ethyl ether MSDS. Available: http://www.sciencelab. com/msds.php?msdsId=9927164
16. Lupulescu E, Ionita E, Botez D, Matepciuc M, Tabra ME, Tecu C, et al. (1997) [An immunogenicity and reactogenicity study of a purified, inactivated trivalent influenza vaccine for parenteral administration prepared for the 1996-1997 season]. Bacteriol Virusol Parazitol Epidemiol 42: 110-112. PMID: 9235136
17. Puri A, Booy FP, Doms RW, White JM, Blumenthal R (1990) Conformational changes and fusion activity of influenza virus hemagglutinin of the H2 and H3 subtypes: effects of acid pretreatment. J Virol 64: 3824-3832. PMID: 2196382
18. Ruigrok RW, Hewat EA, Wade RH (1992) Low pH deforms the influenza virus envelope. J Gen Virol 73 (Pt 4): 995-998. PMID: 1634881
19. Wood JM, Schild GC, Newman RW, Seagroatt V (1977) An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 5: 237-247. PMID: 408355
20. Peterson GL (1977) A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83: 346-356. PMID: 603028
21. MalvernInstrumentsLimited (2011) Inform white paper: Dynamic Light Scattering Common terms defined. http://www.biophysics.bioc.cam.ac.uk/wp-content/uploads/2011/02/DLS-Terms-defined-Malvern.pdf.
22. Harvey R, Wheeler JX, Wallis CL, Robertson JS, Engelhardt OG (2008) Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). Vaccine 26: 6550-6554. doi: 10.1016/j.vaccine.2008.09.050 PMID: 18840494
23. Meiring HD, van der Heeft E, ten Hove GJ, de Jong APJM (2002) Nanoscale LC-MS(n): technical design and applications to peptide and protein analysis. Journal of Separation Science 25: 557-568.
24. Johannsen R, Moser H, Hinz J, Friesen HJ, Gruschkau H (1985) Quantification of haemagglutinin of influenza Tween-ether split vaccines by immunodiffusion. Vaccine 3: 235-240. PMID: 3933204
25. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57: 289-300.
26. Chaloupka I, Schuler A, Marschall M, Meier-Ewert H (1996) Comparative analysis of six European influenza vaccines. Eur J Clin Microbiol Infect Dis 15: 121-127. PMID: 8801083
27. Coenen F, Tolboom JT, Frijlink HW (2006) Stability of influenza sub-unit vaccine. Does a couple of days outside the refrigerator matter? Vaccine 24: 525-531. PMID: 16150515
28. FDA (2015) FDA list of approved vaccines. Available: http://www.fda.gov/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/ucm093833.htm.
29. Cox RJ, Brokstad KA, Ogra P (2004) Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59: 1-15. PMID: 14723616
30. Veit M, Thaa B (2011) Association of influenza virus proteins with membrane rafts. Adv Virol 2011: 370606. doi: 10.1155/2011/370606 PMID: 22312341
31. Vijayakrishnan S, Loney C, Jackson D, Suphamungmee W, Rixon FJ, Bhella D (2013) Cryotomography of budding influenza A virus reveals filaments with diverse morphologies that mostly do not bear a genome at their distal end. PLoS Pathog 9: e1003413. doi: 10.1371/journal.ppat.1003413 PMID: 23754946
32. Delrue I, Verzele D, Madder A, Nauwynck HJ (2012) Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. Expert Rev Vaccines 11: 695-719. doi: 10.1586/erv.12.38 PMID: 22873127
33. Metz B, Kersten GF, Baart GJ, de Jong A, Meiring H, ten Hove J, et al. (2006) Identification of formaldehyde-induced modifications in proteins: reactions with insulin. Bioconjug Chem 17: 815-822. PMID: 16704222
34. Uittenbogaard JP, Zomer B, Hoogerhout P, Metz B (2011) Reactions of beta-propiolactone with nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses. J Biol Chem 286: 36198-36214. doi: 10.1074/jbc.M111.279232 PMID: 21868382
35. Vaarala O, Vuorela A, Partinen M, Baumann M, Freitag TL, Meri S, et al. (2014) Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk. PLoS One 9: e114361. doi: 10.1371/journal.pone.0114361 PMID: 25501681
36. Portela A, Digard P (2002) The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J Gen Virol 83: 723-734. PMID: 11907320
37. Harris A, Forouhar F, Qiu S, Sha B, Luo M (2001) The crystal structure of the influenza matrix protein M1 at neutral pH: M1-M1 protein interfaces can rotate in the oligomeric structures of M1. Virology 289: 34-44. PMID: 11601915
38. Hondt EJD, Engelmann HB (2012) Process for producing influenza vaccine. Espacenet.